The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …

The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

Tuberculosis (TB) is one of the most contagious diseases that has a greater mortality rate
than HIV/AIDS and the cases of TB are feared to rise as a repercussion of the COVID-19 …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

Early diagnosis of tuberculosis (TB), followed by effective treatment, is the cornerstone of
global TB control efforts. An estimated 3 million cases of TB remain undetected each year …

Tuberculosis is one of the deadliest infectious diseases existing in the world since ancient
times and still possesses serious threat across the globe. Each year the number of cases …

N-acyl hydrazone (NAH) is recognized as a promising framework in drug design due to its
versatility, straightforward synthesis, and attractive range of biological activities, including …

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium
tuberculosis. Despite decades of research driving advancements in drug development and …

Osteosarcoma (OS) is the most common primary bone tumor in children and young people.
Traditional surgical excision combined with chemotherapy presents many limitations, such …

Tuberculosis (TB) has been considered as the highly chronic, contagious and infectious
disorder caused by Mycobacterium tuberculosis (Mtb). Every year more than 10 million …